Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

RXRX
Recursion Pharmaceuticals, Inc. Class A Common Stock
stock NASDAQ

At Close
Dec 22, 2025 3:59:49 PM EST
4.39USD+2.934%(+0.13)24,625,064
4.38Bid   4.39Ask   0.01Spread
Pre-market
Dec 23, 2025 9:08:41 AM EST
4.38USD-0.455%(-0.02)132,301
After-hours
Dec 22, 2025 4:57:30 PM EST
4.40USD+0.342%(+0.01)124,997
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Dec 8, 2021
04:40AM EST  SVB Leerink Maintains Outperform on Recursion Pharmaceuticals, Raises Price Target to $32   Benzinga
Dec 7, 2021
08:10AM EST  Biotechnology company Recursion (RXRX) announced Tuesday a collaboration with Roche holding AG (ROG, RHHBY) and Genentech, a member of the Roche Group, to advance novel medicines to patients using machine learning and high content screening methods at scale to map complex biology.   RTTNews
07:59AM EST  Recursion Collaborates With Roche, Genentech In Neuroscience And Oncology   RTTNews
07:58AM EST  Recursion Announces Collaboration With Roche And Genentech In Neuroscience And Oncology; Recursion To Receive $150M Upfront, Says Collaboration Could Yield $300M In Milestones And Royalties   Benzinga
07:55AM EST  Neuroscience and Oncology, Advancing Novel Medicines to Patients Using Machine Learning and High Content Screening Methods at Scale to Map Complex Biology   PR Newswire
Dec 6, 2021
07:58AM EST  Recursion, Bayer Expand Fibrosis Collaboration To Include Inferential Search Capabilities   RTTNews
07:56AM EST  Recursion And Bayer Expand Fibrosis Collaboration To Include Inferential Search Capabilities   Benzinga
07:55AM EST  Recursion and Bayer Expand Fibrosis Collaboration to Include Inferential Search   PR Newswire
Nov 30, 2021
07:55AM EST  Recursion Enhances its Leadership Team and Deepens Focus on Neuroscience with   PR Newswire
Nov 10, 2021
07:56AM EST  Recursion Pharmaceuticals Q3 EPS $(0.28) Up From $(1.09) YoY, Sales $2.53M Up From $1.02M YoY   Benzinga
07:55AM EST  Recursion Provides Business Updates and Reports Third Quarter 2021 Financials   PR Newswire
Oct 12, 2021
08:13AM EDT  The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology   Benzinga
Oct 7, 2021
08:02AM EDT  Recursion (RXRX) said that the U.S. Food and Drug Administration has granted the company Fast Track designation for the investigation of REC-2282 for treatment of patients with NF2-mutated meningiomas, including neurofibromatosis type-2 disease-related meningiomas.   RTTNews
07:58AM EDT  Recursion Granted FDA Fast Track Designation For REC-2282 For Potential Treatment Of NF2-Mutated Meningiomas   RTTNews
07:55AM EDT  Recursion Is Granted FDA Fast Track Designation For REC-2282 For The Potential Treatment Of NF2-Mutated Meningiomas   Benzinga
07:55AM EDT  Recursion is Granted FDA Fast Track Designation for REC-2282 for the Potential   PR Newswire
Sep 29, 2021
08:57AM EDT  Recursion Granted Orphan Drug Designation For REC-4881 For Potential Treatment Of Familial Adenomatous Polyposis   RTTNews
08:54AM EDT  Recursion is Granted Orphan Drug Designation for REC-4881 for the Potential   PR Newswire
Sep 21, 2021
10:33AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For September 21, 2021   Benzinga
07:04AM EDT  Berenberg Initiates Coverage On Recursion Pharmaceuticals with Buy Rating, Announces Price Target of $37   Benzinga
Aug 20, 2021
07:45AM EDT  The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data   Benzinga
Aug 19, 2021
10:57AM EDT  The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck   Benzinga
Aug 18, 2021
07:38AM EDT  The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline   Benzinga
Aug 16, 2021
07:57AM EDT  10 Biggest Price Target Changes For Monday   Benzinga
05:40AM EDT  SVB Leerink Maintains Outperform on Recursion Pharmaceuticals, Lowers Price Target to $30   Benzinga
Aug 13, 2021
08:06AM EDT  Recursion Q2 Net Loss $43.4 Mln Vs. Loss Of $18.9 Mln Prior Year   RTTNews
07:56AM EDT  Recursion Pharmaceuticals Q2 EPS $(0.31) Up From $(0.88) YoY   Benzinga
07:55AM EDT  Recursion Reports Second Quarter 2021 Financials and Provides Business Updates   PR Newswire
Jul 14, 2021
07:48AM EDT  The Daily Biotech Pulse: ScPharma's Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues   Benzinga
Jul 13, 2021
08:05AM EDT  The Daily Biotech Pulse: Equillium Issues Positive Regulatory Update, Biogen In-Licenses Multiple Sclerosis Drug, Aridis Releases COVID-19 Antibody Cocktail Data   Benzinga
07:59AM EDT  Recursion Reports Formation Of A Therapeutics Advisory Board   Benzinga
07:55AM EDT  Recursion Announces Therapeutics Advisory Board, Chaired by Joseph Miletich,   PR Newswire
Jul 12, 2021
04:42PM EDT  Recursion Opens Child Care Center to Support Employees   PR Newswire
Jul 9, 2021
07:36AM EDT  The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO   Benzinga
Jul 7, 2021
07:41AM EDT  The Daily Biotech Pulse: Opiant Spikes On Data, OncoSec Rallies On Merck Collaboration, XBiotech Special Dividend   Benzinga
Jul 1, 2021
08:54AM EDT  Recursion Signs Lease With Vestar for an Additional 100,000 sf of Space at the   PR Newswire
Jun 30, 2021
07:29AM EDT  The Daily Biotech Pulse: COVID Disappointments For Altimmune And Angion, Brickell Jumps On Hyperhidrosis Study Updates, 2 IPOs   Benzinga
Jun 23, 2021
08:56AM EDT  Recursion Announces Multi-Year Collaboration With Mila For Tech-Enabled Drug Discovery   Benzinga
08:53AM EDT  Recursion Announces Multi-Year Collaboration with Mila for Tech-Enabled Drug   PR Newswire
Jun 22, 2021
08:12AM EDT  The Daily Biotech Pulse: Sanofi, Translate Bio Start Early Stage Seasonal Flu Vaccine Study, Dr. Reddy's Launches Generic Vascepa, Halozyme Strikes Licensing Deal   Benzinga
Jun 15, 2021
08:54AM EDT  Recursion Announces its First Major Multidisciplinary Expansion, in Toronto, to   PR Newswire
May 25, 2021
08:32AM EDT  Recursion Pharma Initiates IND-enabling Studies For REC-163964 To Potentially Treat Clostridium Difficile Colitis   RTTNews
08:26AM EDT  Recursion Announces First Internally-Developed NCE Advanced To IND-Enabling Studies To Potentially Treat Clostridium Difficile Colitis   Benzinga
08:25AM EDT  Recursion Announces First Internally-Developed NCE Advanced to IND-Enabling   PR Newswire
May 14, 2021
07:59AM EDT  The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts   Benzinga
May 12, 2021
09:43AM EDT  Recursion Q1 Net Loss $30.7 Mln Vs. Net Loss $18.4 Mln Prior Year   RTTNews
08:57AM EDT  The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron   Benzinga
08:46AM EDT  Recursion Pharmaceuticals Q1 EPS $(1.33) Down From $(0.85) YoY, Sales $2.56M Up From $60.00K YoY   Benzinga
08:45AM EDT  Recursion Reports First Quarter 2021 Financials and Provides Business Updates   PR Newswire
May 11, 2021
10:07AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2021   Benzinga
08:45AM EDT  SVB Leerink Initiates Coverage On Recursion Pharmaceuticals with Outperform Rating, Announces Price Target of $33   Benzinga
07:54AM EDT  The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings   Benzinga
07:45AM EDT  B of A Securities Initiates Coverage On Recursion Pharmaceuticals with Buy Rating, Announces Price Target of $31   Benzinga
07:31AM EDT  JP Morgan Initiates Coverage On Recursion Pharmaceuticals with Neutral Rating, Announces Price Target of $32   Benzinga
06:44AM EDT  Goldman Sachs Initiates Coverage On Recursion Pharmaceuticals with Neutral Rating, Announces Price Target of $34   Benzinga
05:56AM EDT  Keybanc Initiates Coverage On Recursion Pharmaceuticals with Overweight Rating, Announces Price Target of $36   Benzinga
May 4, 2021
09:16AM EDT  Cathie Wood Loads Up More On Alibaba Rivals Pinduoduo, JD Also Adds Skillz   Benzinga
Apr 30, 2021
10:19AM EDT  Cathie Wood Piles Up Teladoc As Shares Slump On Q1 Miss, Also Adds More Tesla   Benzinga
Apr 22, 2021
08:09AM EDT  The Daily Biotech Pulse: KemPharm Receives $10M Milestone Payment, Zymergen, Neuropace Debut On Nasdaq, Renalytix Wins US Government Contract, 2 IPOs   Benzinga
Apr 21, 2021
08:01AM EDT  Recursion Pharmaceuticals Announces Closing of Initial Public Offering   PR Newswire
Apr 19, 2021
10:27AM EDT  Mid-Morning Market Update: Markets Open Lower; Coca-Cola Tops Q1 Views   Benzinga
Apr 16, 2021
02:51PM EDT  Mid-Afternoon Market Update: Dow Surges 170 Points; Mer Telemanagement Solutions Shares Spike Higher   Benzinga
12:58PM EDT  Mid-Day Market Update: General Finance Climbs Following Acquisition News; PHX Minerals Shares Drop   Benzinga
12:42PM EDT  Recursion Pharmaceuticals Shares Open For Trade At $30; IPO Priced At $18/Share   Benzinga
12:16AM EDT  Recursion Pharma Reports Pricing Of IPO Of Class A Common Stock At $18/Shr   RTTNews
12:13AM EDT  Recursion Pharmaceuticals Announces Pricing of Initial Public Offering   PR Newswire


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-5
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC